Who we are
What we do, our journey and our values.About us
RECORNEA is a clinical stage medtech ophthalmic company developing therapeutic solutions for treating diseases of the eye.
Our Mission
We aim at enhancing the quality of the daily life of our patients through revolutionary solutions.
Our Vision
We believe in preventing blindness through developing innovative medical (bio)-technology solutions.
Our Values
Innovation, Quality, Integrity.
Our Journey
The history of Recornea by key facts:
-
2025
Closing Seed investment from Health Wildcatters, BHeroes, Caique Holding, DN Lemans, Scientifica and ENEA Tech e Biomedical
-
2025
Recornea new office in Trieste.
-
2024
Start of the First In Human clinical trial of GROSSO® Reshaper in keratoconus patients.
-
2024
In vivo preclinical study on rabbits completed for GROSSO® Reshaper.
-
2023
Recornea received the ESCRS innovation award at the Innovation Den.
-
2023
In vitro preclinical study completed for GROSSO® Reshaper.
-
2023
ISO 13485:2016 certification of the QMS as the legal manufacturer of the GROSSO® Reshaper.
-
2023
The GROSSO® Reshaper presented at the congress ESCRS for the first time in public.
-
2021
Closing pre-seed investment from Entrepreneur First Singapore, Entrepreneur First UK, GFactor and Health Wildcatters.
-
2020
Recornea relocation to Italy (HQ Trieste).
-
2019
Recornea foundation in Singapore.
What we do
Our core technology couples minimally invasive surgery with minimally invasive biocompatible and bioenhanced devices to treat eye conditions for the following applications: